BTT-T739 Syngeneic Model Service for Bladder Cancer

The BTT-T739 syngeneic model of bladder cancer grows a carcinogen-induced murine urothelial carcinoma in fully immunocompetent T739 hosts, preserving the tumor-immune interplay that immunodeficient xenografts cannot capture. From authenticated cell expansion and subcutaneous implantation to caliper-based efficacy readouts, lung metastasis scoring and tumor-immune profiling, Alfa Cytology delivers complete BTT-T739 syngeneic study programs configured around each sponsor’s agent, schedule and endpoint needs—strictly within preclinical research.

Overview of BTT-T739 Syngeneic Model for Bladder Cancer

BTT-T739 arose from one of the classic chemical-carcinogenesis programs in Chinese bladder cancer research: an N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)–induced bladder tumor was generated in the inbred T739 mouse strain, and the resulting poorly differentiated transitional (urothelial) carcinoma was adapted to culture, yielding a line that retains syngeneic compatibility with its host. Systematic reviews of bladder cancer models place BTT-T739 among the murine lines reflecting muscle-invasive, high-grade disease. The cells grow as adherent monolayers in RPMI-1640 with 10% serum and have carried decades of investigation—from some of the earliest cytokine gene-therapy experiments, in which interleukin-2 and interferon-γ were used to arm tumor-cell vaccines, to studies of interleukin-6, mitomycin C, low-dose cyclophosphamide, radiation combinations, and VEGF-driven angiogenesis using a GFP-tagged derivative.

Fig 1. H&E histology of orthotopic BTT-T739 bladder tumors: papillary fronds, invasive transitional carcinoma nests, and stromal invasion patterns (panels A–D). (Yang, Xi-hua, et al., 2012)

As a syngeneic model, BTT-T739 engrafts in immunologically intact T739 recipients, making it a natural testbed for immunotherapy, vaccine, cytokine and metronomic-chemotherapy questions rather than a platform for human-cell biology. Subcutaneous implantation of around one million cells produces tumors that are palpable within about a week and progress in essentially all recipients, with pulmonary metastases available for scoring at necropsy; an orthotopic intravesical variant is equally well documented, in which instillation of one million cells onto mechanically injured bladder mucosa yields a 100% tumor take, a mean survival near 27 days, and visceral metastasis in roughly a quarter of animals. Practical caveats deserve mention: the line grows briskly, compressing treatment windows; the T739 strain is maintained by relatively few institutions, so host availability can constrain study design; and the relevance of rodent urothelial biology to human disease remains a point of open discussion in the literature. Within those boundaries, the model offers an affordable, immunologically intact, and historically well-characterized venue for preclinical bladder cancer studies.

Cell Line Information: BTT-T739

Key characteristics of BTT-T739 and its documented derivatives are summarized below.

Our Services

Leveraging in vivo oncology specialists and integrated pathology and immune-profiling workflows, Alfa Cytology shapes every BTT-T739 syngeneic engagement to the sponsor’s hypothesis—calibrating inoculum format, randomization timing, dosing schedule and endpoint panels so each study yields clean, decision-grade preclinical evidence.

Workflow of BTT-T739 Syngeneic Model Construction

Construction of the BTT-T739 syngeneic model is a straightforward implantation workflow with rigorous quality gates: verified cells, healthy syngeneic recipients, consistent inoculation technique and disciplined measurement schedules. The process typically proceeds through the following stages:

1. Cell line qualification: BTT-T739 vials are mycoplasma-tested and identity-verified; viability is confirmed by trypan blue exclusion before expansion, and luciferase labeling can be engineered up front where imaging-based designs are required.
2. Animal preparation: T739 inbred mice (typically 6–8 weeks old) are acclimatized, health-screened and ear-marked for individual tracking ahead of implantation.
3. Cell preparation: cells are harvested at log phase, washed and counted, then resuspended in PBS at the working concentration (commonly 1 × 10⁷/mL for a 100 µL injection); a 2 mm³ tumor-fragment format is prepared in parallel where specified.
4. Subcutaneous inoculation: 100 µL of the cell suspension (1 × 10⁶ cells) is injected into the flank with a fine needle, or tumor fragments are tamped into a small subcutaneous pocket, with consistent site selection to support reproducible caliper measurement.
5. Randomization: once tumors become palpable (typically by day 7), mice are measured and assigned to treatment groups by tumor volume and body weight to balance baseline burden.
6. Treatment and monitoring: test articles are dosed per protocol; tumors are measured with calipers two to three times weekly (volume commonly computed as 0.52 × width × length²), alongside body weight and clinical scoring.
7. Endpoint and analysis: at termination, tumors are excised and weighed, lungs and abdominal viscera are inspected for metastasis, and tissues are processed for histopathology, immunohistochemistry, flow-cytometric immune profiling and molecular assays.

Fig 2. BTT-T739 Syngeneic Model construction workflow.

Case Study-BTT-T739 Syngeneic Model Development

Alfa Cytology curates a growing preclinical case-study collection for the BTT-T739 syngeneic platform, covering establishment-phase optimization of inoculum format and dose, caliper-based efficacy tracking in vivo, immunotherapy and combination-regimen intervention studies, and systematic pulmonary and visceral metastasis evaluation with matched immune-phenotyping. Illustrative materials—including growth curves, endpoint summaries and immune-profiling data—are available on request and are refreshed as further programs conclude.

Why Choose Alfa Cytology?

Sponsors select Alfa Cytology for this model because an immunocompetent syngeneic platform rewards operational consistency at every step:

• A disciplined implantation team delivering uniform, high-take subcutaneous and fragment-based inoculation.
• Authenticated BTT-T739 banks with GFP or luciferase labeling available for imaging-based designs.
• An immunologically intact T739 host that supports immunotherapy, vaccine and cytokine questions.
• Structured caliper monitoring with volume-balanced randomization to tighten group comparability.
• A configurable endpoint menu spanning efficacy, metastasis scoring, histopathology, IHC and flow cytometry.
• Sensitivity to the model’s brisk kinetics, with dosing schedules designed to fit compressed windows.
• Responsive, single-point project communication with milestone-based progress reporting.
• An exclusively preclinical mandate, with all studies designed, conducted and reported as non-clinical research.

Contact Us

If the BTT-T739 syngeneic bladder cancer model fits your next preclinical objective, contact us to share your agent, timeline and preferred endpoints. The Alfa Cytology team will reply with a customized plan covering model setup, dosing strategy and analysis workflow—reach out today and advance your program with confidence.

For research use only. Not intended for any clinical use.